SITE-SPECIFIC RADIOISOTOPE-LABELED ANTIBODY USING IgG-BINDING PEPTIDE
AssigneeKagoshima University
InventorsYuji ITO, Yoshinari SHOYAMA, Akio HAYASHI, Norihito NAKATA
Life of this patent
Estimating the term…
Abstract
The present invention relates to an IgG-binding peptide comprising a ligand capable of binding to a radioactive metal nuclide, an IgG-binding peptide labeled with a radioactive metal nuclide, a conjugate of the IgG-binding peptide and IgG, and a radionuclide imaging agent or a diagnostic agent for cancer comprising the IgG-binding peptide or the conjugate, etc.
Claims28
A conjugate comprising a peptide, IgG, and a ligand, wherein the peptide comprises an amino acid sequence consisting of 13 to 17 amino acid residues represented by the following formula I:
- (SEQ ID NO:
- 38)
- (X1-3)-C-(X2)-H-(Xaa1)-G-(Xaa2)-
- L-V-W-C(X1-3) (I)
- wherein each X is independently any amino acid residue other than cysteine,
- C is a cysteine residue,
- H is a histidine residue,
- Xaa1 is a lysine residue, a cysteine residue, an aspartic acid residue, a glutamic acid residue, 2-aminosuberic acid, or diaminopropionic acid,
- G is a glycine residue,
- Xaa2 is a glutamic acid residue, a glutamine residue, or an asparagine residue,
- L is a leucine residue,
- V is a valine residue, and
- W is a tryptophan residue,
- wherein the peptide is capable of binding to a human IgG via a cross-linking agent which modifies at Xaa1, and wherein the ligand is capable of binding a radioactive metal nuclide and is linked to the N terminus of the peptide.
A peptide which comprises an amino acid sequence consisting of 13 to 17 amino acid residues represented by the following formula I:
- (SEQ ID NO:
- 38)
- (X1-3)-C-(X2)-H-(Xaa1)-G-(Xaa2)-
- L-V-W-C(X1-3) (I)
- wherein each X is independently any amino acid residue other than cysteine,
- C is a cysteine residue,
- H is a histidine residue,
- Xaa1 is a lysine residue, a cysteine residue, an aspartic acid residue, a glutamic acid residue, 2-aminosuberic acid, or diaminopropionic acid,
- G is a glycine residue,
- Xaa2 is a glutamic acid residue, a glutamine residue, or an asparagine residue,
- L is a leucine residue,
- V is a valine residue, and
- W is a tryptophan residue,
- wherein the peptide is capable of binding to human IgG, and is labeled with a radioactive metal nuclide,
- wherein the radioactive metal nuclide is bound to the peptide via a ligand, and
- wherein the ligand is linked to the N terminus.
Dependencies are inferred from the claim text.